Left atrial function and NT-proANP as markers of AF progression and impaired outcome in patients with heart failure with preserved ejection fraction
Well, it’s been a really rough three weeks. The first thing that happened was on January 1, no kidding, when I came down with a case of the flu (much worse than the before-Xmas flu). It’s going around. A lot of people are sick with this thing. Anyway, it hit me with a very high fever and huge gastrointestinal issues. Terrible. Plus, one night, delirious with fever, I fell against the bathroom wall and injured my wrist. Ouch. Because my wrist was all swollen and hurt like the dickens, and I feared it might be fractured, Stefano took me to the emergency room at Florence’s university hospital, Careggi. We sp...
Acute heart failure is a rapid onset of new or worsening of signs and symptoms of heart failure that requires hospitalization or a visit to the emergency department. The aim of this study was to evaluate treat...
AbstractOver the recent years, studies have emerged reporting on a strong relationship between the occurrence of malignancy and Takotsubo syndrome. The aim of this systematic review and meta-analysis is to evaluate the predictive value of malignancy for prognosis of Takotsubo syndrome patients. PubMed, EMBASE, Cochrane Library, Web of science, and Scopus were searched until 4 September 2019 for articles concerning association of malignancy with the prognosis of Takotsubo syndrome. A total of ten studies were finally included in this meta-analysis, demonstrating that malignancy was associated with higher mortality in Takots...
AbstractReceptor tyrosine kinases (RTKs) are implicated in cardiovascular growth and remodelling. We aimed to identify the plasma levels of RTKs and related proteins and their association with haemodynamic alterations in heart failure (HF) and related pulmonary hypertension (PH) following heart transplantation (HT). Using proximity extension assay, 28 RTKs and related proteins were analysed in plasma from 20 healthy controls and 26 HF patients before and 1-year after HT. In end-stage HF, out of 28 RTKs, plasma vascular endothelial growth factor-D (VEGF-D) and human epidermal growth factor-4 (HER4) were elevated compared to controls (p
ConclusionsSurvey results highlight that cardiologists in Switzerland would benefit from information on the latest advances in ATTR to support them in screening heart failure patients and ensure that patients benefit from treatment advances.
Conclusion: The presence of clinically significant TR is associated with an increase in healthcare utilization and expenditures, irrespective of the presence of HF. PMID: 31952454 [PubMed - as supplied by publisher]
Patients with heart failure with reduced ejection fraction (HFrEF) can be treated with mineralocorticoid receptor antagonists (MRAs) and are unlikely to develop hypotension as a result, an analysis of two large randomized trials reveals.Reuters Health Information
We read with interest the article by Couselo-Seijas et al. “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment” . The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) is gradually increasing in diabetes mellitus (DM) and heart failure treatment. Increasing pieces of n ovel information are added to the literature on these drugs. We strongly agree with the authors' findings. The article has led us to consider lactate levels in euglycemic (E) diabetic ketoacidosis (DKA) due to SGLT2i use, and the usefulness of metformin and SGLT-2i combination.
Conclusion: The efficacy and additional benefits of FZF for CCEs were certain according to the high-quality evidence assessed through GRADE. However, the efficacy and additional benefits for the other outcomes were uncertain judging from current studies. In addition, the safety assessment has a great room for improvement. Thus, further research studies are needed to find more convincing proofs. PMID: 31949473 [PubMed]
ConclusionsThis study demonstrated a vital role of calpain in ECs for inducing myocardiocyte hypertrophy, cell death and the EndMT via the HSP90/Akt signaling pathway, thereby promoting cardiac fibrosis. The results indicate that inhibiting ECs calpain is a novel therapeutic target to retard cardiac fibrosis and has positive effects on heart failure.Graphical abstract